Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis

Abstract

Our meta-analysis showed hepatic arterial infusion chemotherapy provided better tumor response and survival benefits than Sorafenib for advanced hepatocellular carcinoma and should be recommended as an alternative treatment option.

Sorafenib is more effective in the treatment of TACE-refractory hepatocellular carcinoma than hepatic arterial infusion chemotherapy: a meta-analysis

“…Through systematic literature retrieval, a total of 5 articles were included in this study. Different from the conclusion of previous systematic reviews [27][28][29], the study showed that sorafenib could prolong the overall survival of patients with TACE-refractory HCC compared with HAIC (HR = 1.69, 95% CI [1.09, 2.62], p=0.018). Although the ORR of the HAIC group was significantly higher than that of the sorafenib group (RR = 3.08, 95%CI [1.38, 6.87], p=0.006), the DCR between the HAIC group and the sorafenib group was not significantly different (RR = 0.94, 95%CI [0.60, 1.48], p=0.798).…”

“…Previous studies suggest that compared with sorafenib, patients in the HAIC group have a lower incidence of AEs in the treatment process and higher safety, especially when HCC is combined with portal vein tumor thrombosis [12,27,41]. Both the HAIC group and the sorafenib group, there were cases of discontinuation of treatment due to AEs.…”

“…Compared with sorafenib, HAIC shows a better therapeutic effect and a lower incidence of adverse events (AEs) in the treatment of advanced or unresectable HCC [27][28][29]. HAIC has been widely used in Japan [12].…”

Clinical characteristics analysis of 1180 patients with hepatocellular carcinoma secondary to hepatitis B, hepatitis C and alcoholic liver disease

“…The incidence of HCC in China accounts for more than 55% worldwide . Only 30%‐40% of HCC patients can receive radical treatment, which seriously threatens people's life and health …”

“…3 Only 30%-40% of HCC patients can receive radical treatment, which seriously threatens people's life and health. 4 The highest liver cancer rates are found in East and Southeast Asia and in Middle and Western Africa. This difference in incidence of liver cancer between different geographical regions and countries is mainly attributed to difference in the incidence of underlying risk factors.…”